| Name | Title | Contact Details |
|---|
Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities.
A disruptive new biopharmaceutical CDMO, we are pushing the boundaries of biomanufacturing and solving an outdated industry bottleneck with a unique partnering model. By bringing together biologics drug innovators, discovery CROs, and CDMOs, we are accelerating the translation of therapeutic innovation to clinical impact.
RareCyte is a company focused on characterizing and isolating rare cells from blood.
Novan, Inc. is a clinical-stage biotechnology company focused on leveraging nitric oxide`s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. We believe that our ability to conveniently deploy nitric oxide in a solid form, on demand and in localized formulations allows us the potential to significantly improve patient outcomes in a variety of diseases.
The mission of Proteonomix, Inc. is to achieve a leadership position in life enhancement regenerative stem cell therapies, services, and products through a combination of first to market technologies, and innovative clinical trial strategies.